167 related articles for article (PubMed ID: 9052418)
41. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.
Ellmén J; Werner D; Hakulinen P; Keiling R; Fargeot P; Falkson G; Bezwoda WR
Cancer Chemother Pharmacol; 2000; 45(5):402-8. PubMed ID: 10803924
[TBL] [Abstract][Full Text] [Related]
42. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
43. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
44. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
45. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.
Gylling H; Pyrhönen S; Mäntylä E; Mäenpää H; Kangas L; Miettinen TA
J Clin Oncol; 1995 Dec; 13(12):2900-5. PubMed ID: 8523053
[TBL] [Abstract][Full Text] [Related]
46. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
47. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.
Buzdar AU; Hortobagyi GN
J Clin Oncol; 1998 Jan; 16(1):348-53. PubMed ID: 9440763
[TBL] [Abstract][Full Text] [Related]
48. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
Kim M; Kim H; Ahn SH; Tabatabaie V; Choi SW; Sohn G; Lee SB; Ko BS; Chung IY; Kim J; Lee JW; Son BH; Kim HJ
Breast Cancer Res Treat; 2020 Apr; 180(3):657-663. PubMed ID: 32072339
[TBL] [Abstract][Full Text] [Related]
49. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients.
Tomás E; Kauppila A; Blanco G; Apaja-Sarkkinen M; Laatikainen T
Gynecol Oncol; 1995 Nov; 59(2):261-6. PubMed ID: 7590484
[TBL] [Abstract][Full Text] [Related]
50. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
[TBL] [Abstract][Full Text] [Related]
51. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.
Kristensen B; Ejlertsen B; Dalgaard P; Larsen L; Holmegaard SN; Transbøl I; Mouridsen HT
J Clin Oncol; 1994 May; 12(5):992-7. PubMed ID: 8164053
[TBL] [Abstract][Full Text] [Related]
52. Does long-term administration of tamoxifen affect bone mineral density?
Neal AJ; Evans K; Hoskin PJ
Eur J Cancer; 1993; 29A(14):1971-3. PubMed ID: 8280491
[TBL] [Abstract][Full Text] [Related]
53. Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia.
Leslie WD; Cowden EA; Maclean JP
Nucl Med Commun; 1995 Aug; 16(8):698-702. PubMed ID: 7491184
[TBL] [Abstract][Full Text] [Related]
54. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.
Wallén M; Tomás E; Visakorpi T; Holli K; Mäenpää J
Cancer Chemother Pharmacol; 2005 Apr; 55(4):343-346. PubMed ID: 15592834
[TBL] [Abstract][Full Text] [Related]
55. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
[TBL] [Abstract][Full Text] [Related]
56. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
57. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
58. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
59. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
[TBL] [Abstract][Full Text] [Related]
60. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis.
Chi F; Wu R; Zeng Y; Xing R; Liu Y; Xu Z
Breast Cancer; 2013 Apr; 20(2):111-22. PubMed ID: 23266963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
